Last week it was once again time for the big investor and partnering meeting focused on life science, the LSX World Congress in London. The sixth edition of the congress offered companies, investors and VC funds two days of exciting company presentations, seminars and meetings. One of the companies that took the opportunity to introduce themselves to the international market was Swedish Iconovo, which develops inhalers with associated drug formulations. BioStock was in London and had a chat with Iconovo’s CEO Orest Lastow about the company’s participation in the congress, as well as its business strategy and upcoming restructuring.
See the interview with Orest Lastow from LSX World Congress in London here – English subtitles are available:
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.